HRT Financial’s C4 Therapeutics CCCC Stock Holding History

HRT Financial’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$428K	Buy	+162,930	New	+$384K	﹤0.01%	2644
2025 Q3	–	Sell	-71,106	Closed	-$101K	–	2913
2025 Q2	$101K	Buy	71,106 +58,072	+446%	+$84.5K	﹤0.01%	2209
2025 Q1	$20K	Buy	+13,034	New	+$38.9K	﹤0.01%	2302
2023 Q2	–	Sell	-119,612	Closed	-$375K	–	2537
2023 Q1	$375K	Buy	+119,612	New	+$704K	﹤0.01%	1576
2022 Q4	–	Sell	-57,088	Closed	-$500K	–	2519
2022 Q3	$500K	Sell	57,088 -38,653	-40%	-$401K	0.01%	1536
2022 Q2	$721K	Buy	+95,741	New	+$842K	0.01%	1230

Other funds holding CCCC

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

HRT Financial's CCCC Position: Q1 2026 in Review

HRT Financial opened a new position in C4 Therapeutics (CCCC) in Q1 2026: 162,930 shares worth $428K. The stake represents ﹤0.01% of the portfolio and ranks #2644 among its holdings. This is a return to the name: HRT Financial previously reported a position in CCCC as recently as Q2 2025.

HRT Financial first reported a position in CCCC in Q2 2022 and has held it in 6 quarters since. The position peaked at $721K in Q2 2022. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

HRT Financial held 162,930 shares of C4 Therapeutics worth $428K as of Q1 2026.
C4 Therapeutics was a new HRT Financial position in Q1 2026.
C4 Therapeutics made up ﹤0.01% of HRT Financial's portfolio in Q1 2026, its #2644 holding.
HRT Financial first reported a position in C4 Therapeutics in Q2 2022 and has held it in 6 quarters since.
HRT Financial's C4 Therapeutics position peaked at $721K in Q2 2022.
123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.